Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 90,600 shares, an increase of 19.2% from the February 13th total of 76,000 shares. Based on an average trading volume of 102,400 shares, the short-interest ratio is currently 0.9 days. Currently, 1.1% of the shares of the company are short sold.
Avalo Therapeutics Stock Down 6.8 %
AVTX traded down $0.56 during midday trading on Friday, reaching $7.66. The company had a trading volume of 33,867 shares, compared to its average volume of 210,442. Avalo Therapeutics has a 12-month low of $4.60 and a 12-month high of $34.46. The business has a 50-day moving average price of $7.45 and a two-hundred day moving average price of $9.11.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its position in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics during the 4th quarter worth $145,000. Northern Trust Corp purchased a new position in Avalo Therapeutics in the fourth quarter worth $168,000. Finally, Bank of Montreal Can purchased a new stake in Avalo Therapeutics during the fourth quarter valued at about $446,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms recently commented on AVTX. BTIG Research started coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $40.00 price target for the company. Wedbush restated an "outperform" rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday. Piper Sandler started coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an "overweight" rating and a $48.00 price target on the stock. Finally, HC Wainwright restated a "neutral" rating on shares of Avalo Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.33.
Get Our Latest Research Report on Avalo Therapeutics
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Further Reading
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
